The desire to limit blood use in oncologic surgery originated with the finding of increased immunosuppression in patients who received transfusions while undergoing a renal transplant.1 Subsequently, an association was demonstrated between transfusion and increased rates of cancer recurrence and worse overall oncologic prognosis,2 with the results being most pronounced for transabdominal oncologic procedures.3,4